<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01183117</url>
  </required_header>
  <id_info>
    <org_study_id>SM-01</org_study_id>
    <nct_id>NCT01183117</nct_id>
  </id_info>
  <brief_title>A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery Disease</brief_title>
  <official_title>A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson K.K. Medical Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson K.K. Medical Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to evaluate the safety and efficacy of SM-01 stenting (Cordis&#xD;
      S.M.A.R.T.â„¢ Nitinol Stent System) for the treatment of SFA lesions as compared to PTA&#xD;
      (balloon angioplasty). If SM-01 is used in a PTA-bailout patient, the case will be assessed&#xD;
      separately.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-TVF(Target-vessel failure) rate</measure>
    <time_frame>12 Months</time_frame>
    <description>The primary endpoint will be freedom from TVF defined as any events of clinical driven (confirmed by duplex ultrasound or angiography) TLR/TVR, procedure failure, amputation of the target lesion's leg, procedure or device related death, occlusion of target lesion, or &gt; 70% restenosis of target lesion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure Success rate</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Success rate for Bailout</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between pre and post proceduer of ABI</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between pre and post procedure of Rutherford Categories</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-TLR/TVR rate</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Patency rate</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Fracture rate</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between pre and post procedure of QOL (SF-36)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Clinical Event rate</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Peripheral Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>SM-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PTA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SM-01</intervention_name>
    <description>SM-01 is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
    <arm_group_label>SM-01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTA</intervention_name>
    <description>balloon angioplasty</description>
    <arm_group_label>PTA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;= 20 years.&#xD;
&#xD;
          2. Symptomatic leg ischemia by Rutherford Classification (category1, 2, or 3).&#xD;
&#xD;
          3. Lesion length &gt;= 40 mm to &lt;= 150 mm. (must be treatable with no more than two SM-01&#xD;
             stents. Overlap should be about 1cm if two stents are used)&#xD;
&#xD;
          4. Reference vessel diameter (RVD) &gt;= 4.0 mm and &lt;= 7.0 mm.&#xD;
&#xD;
          5. All lesions are to be located &gt;= 3.0 cm proximal to the superior edge of the patella,&#xD;
             and &gt;= 1.0 cm distal to the SFA / PFA bifurcation.&#xD;
&#xD;
          6. &gt;= 50% stenosis or total occlusion.&#xD;
&#xD;
          7. Patent infrapopliteal and popliteal arteries, i.e., single-vessel runoff or better&#xD;
             with at least one of three vessels patent (&lt; 50% stenosis) to the ankle or foot.&#xD;
&#xD;
          8. Patient or legally authorized representative must provide written informed consent&#xD;
             prior to initiation of study procedures.&#xD;
&#xD;
          9. A patient with bilateral obstructive SFA disease is eligible for enrollment into the&#xD;
             study. If a patient with bilateral disease is enrolled, the target limb will be the&#xD;
             more severe limb. The more severe limb will be selected according to clinical&#xD;
             symptomatology. If clinical symptomatology is similar, the more clinically severe&#xD;
             lesion will be selected. The contralateral procedure should not be done until at least&#xD;
             30 days after the index procedure of the more severe limb was attempted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recent hemorrhagic disease within the past 3 months.&#xD;
&#xD;
          2. Aneurysm in the SFA or popliteal artery.&#xD;
&#xD;
          3. Acute limb occlusion.&#xD;
&#xD;
          4. Procedures which are pre-determined to require stent-in-stent placement to obtain&#xD;
             patency, such as severe calcification which is resistant to stenting, or for in-stent&#xD;
             restenosis.&#xD;
&#xD;
          5. Poor iliac or common femoral &quot;inflow&quot;.(However, intervention to restore adequate blood&#xD;
             flow prior to the treatment of the study lesion is allowed.)&#xD;
&#xD;
          6. Known allergies to aspirin, heparin, or ticlopidine, or bleeding diathesis.&#xD;
&#xD;
          7. Patients unable or unwilling to tolerate anticoagulant or antiplatelet therapy.&#xD;
&#xD;
          8. Patients unable or unwilling to tolerate contrast agents used in intravascular&#xD;
             procedures.&#xD;
&#xD;
          9. Allergic to nitinol or tantalum.&#xD;
&#xD;
         10. Women who are pregnant or lactating, or of child bearing potential, or with a desire&#xD;
             to be a parent during the study period.&#xD;
&#xD;
         11. Significant vessel tortuosity or other parameters prohibiting access to the lesion or&#xD;
             which would prevent delivery of the stent device.&#xD;
&#xD;
         12. Revascularization involving the same limb 30 days prior to the index procedure or a&#xD;
             planned re-vascularization within 30 days after the index procedure.&#xD;
&#xD;
         13. Previously implanted stent(s) at the same site in the artery to be treated.&#xD;
&#xD;
         14. Requiring stent placement in the distal SFA or popliteal artery.&#xD;
&#xD;
         15. Presence of a femoral artificial graft.&#xD;
&#xD;
         16. History of participating in any other clinical study within 1 year.&#xD;
&#xD;
         17. Life expectancy less than 3 years, or any other factors preventing clinical follow-up.&#xD;
&#xD;
         18. Receiving dialysis or immunosuppressant therapy&#xD;
&#xD;
         19. Serum creatinine level &gt;= 2.0 mg/dL before procedure.&#xD;
&#xD;
         20. A principal investigator or a co-principal investigator determines that patient is&#xD;
             unsuitable for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hidehiko Hara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toho University Ohashi Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toho University Ohashi Medical Center</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>August 1, 2010</study_first_submitted>
  <study_first_submitted_qc>August 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2010</study_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

